Drug usage and costs of pneumonia inpatients in Karamay Central Hospital in 2014_Chinese Journal of Evidence-Based Medicine

Authors：

ZHANG Shengzhao ¹ , YU Jiajie ² ,  LIU Jianhong ¹ ,  LI Youping ² , ZHANG Weidong ¹ , XU Ting ³ , WU Min ¹ , LU Jing ³ , ZHAO Junfang ¹ , SUN Xin ² , SU Guanyue ²

1. Department of Pharmacy, Karamay Central Hospital, Karamay, 834000, P.R.China;
2. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
3. Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding?author：

LIU Jianhong, Email: liuxyf001@126.com; LI Youping, Email: yzmylab@hotmail.com

Keywords：

Inpatients; Single disease; Pneumonia; Evidence-based pharmacy; Rational drug use

DOI：

10.7507/1672-2531.201608043

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate drug usage and costs of pneumonia inpatients in Karamay Central Hospital in 2014 and to provide baseline for evidence-based pharmacy study of single disease in respiratory system. Methods The information of drug use and expenditure of pneumonia inpatients were collected from the hospital information system (HIS). We analyzed the data including frequency, proportion and cumulative proportion by Excel 2007 software. Results A total of 309 inpatients were included, among the 78.96% were more than 60 years old. Among the antibiotics single therapy, the frequency of cefoperazone and sulbactam was the highest. Among the antibiotics combination therapy, the frequency of β-lactam antibiotics was the highest. Conclusion Pneumonia inpatients in Karamay Central Hospital are mainly older patients. The β-lactam antibiotics is used most in clinical practice.

Citation： ZHANG Shengzhao, YU Jiajie, LIU Jianhong, LI Youping, ZHANG Weidong, XU Ting, WU Min, LU Jing, ZHAO Junfang, SUN Xin, SU Guanyue. Drug usage and costs of pneumonia inpatients in Karamay Central Hospital in 2014. Chinese Journal of Evidence-Based Medicine, 2017, 17(8): 880-883. doi: 10.7507/1672-2531.201608043 Copy

1.	Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA, 1996, 275(2): 134-141.
2.	中華醫學會呼吸病學分會. 中國成人社區獲得性肺炎診斷和治療指南 (2016 年版). 中華結核和呼吸雜志, 2016, 39(4): 253-279.
3.	劉慧, 肖新才, 陸建云, 等. 2009-2012 年廣州市社區獲得性肺炎流行特征和病原學研究. 中華預防醫學雜志, 2013, 47(12): 1089-1094.
4.	《抗菌藥物臨床應用指導原則》修訂工作組. 抗菌藥物臨床應用指導原則 (2015 年版). 北京: 人民衛生出版社, 2015: 1-20.
5.	Miyashita N, Matsushima T, Oka M. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med, 2006, 45(7): 419-428.
6.	Corrêa-Rde A, Lundgren FL, Pereira-Silva JL, et al. Brazilian guidelines for community-acquired pneumonia in immunocompetent adults - 2009. J Bras Pneumol, 2009, 35(6): 574-601.
7.	Wiersinga WJ, Bonten MJ, Boersma WG, et al. SWAB /NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults. Neth J Med, 2012, 70(2): 90-101.
8.	Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis, 2007, 44(Suppl 2): 27-72.
9.	Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect DIS, 2000, 31(2): 347-382.
10.	Tao LL, Hu BJ, He LX, et al. Etiology and antimicrobial resistance of community-acquired pneumonia in adults patients in China. Chin Med J, 2012, 125(17): 2967-2972.
11.	劉又寧, 陳民均, 趙鐵梅, 等. 中國城市成人社區獲得性肺炎 665 例病原學多中心調查. 中華結核和呼吸雜志, 2006, 29(1): 3-8.
12.	王輝, 劉亞麗, 陳民均, 等. 2009-2010 年中國六城市成人社區獲得性呼吸道感染病原菌耐藥性監測. 中華結核和呼吸雜志, 2012, 35(2): 113-119.
13.	趙春江, 張菲菲, 王占偉, 等. 2012 年中國成人社區獲得性呼吸道感染主要致病菌耐藥性的多中心研究. 中華結核和呼吸雜志, 2015, 38(1): 18-22.
14.	Liu Y, Ye X, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother, 2009, 53(5): 2160-2162.
15.	尹玉東, 曹彬, 王輝, 等. 北京地區成人社區獲得性肺炎患者中肺炎支原體耐藥情況的多中心調查. 中華結核和呼吸雜志, 2013, 36(12): 954-958.
16.	尹玉東, 曹彬. 社區獲得性肺炎診治指南解讀: 從病情嚴重度分層角度. 中國循證醫學雜志, 2015, 15(7): 756-760.
17.	Mills GD, Oehley MR, Arrol B. Effectiveness of β lactam antibiotics compared with antibiotics active against pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ, 2005, 330(7489): 456.
18.	Eccles S, Pincus C, Higgins B, et al. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ, 2014, 349: 6722.

1. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA, 1996, 275(2): 134-141.
2. 中華醫學會呼吸病學分會. 中國成人社區獲得性肺炎診斷和治療指南 (2016 年版). 中華結核和呼吸雜志, 2016, 39(4): 253-279.
3. 劉慧, 肖新才, 陸建云, 等. 2009-2012 年廣州市社區獲得性肺炎流行特征和病原學研究. 中華預防醫學雜志, 2013, 47(12): 1089-1094.
4. 《抗菌藥物臨床應用指導原則》修訂工作組. 抗菌藥物臨床應用指導原則 (2015 年版). 北京: 人民衛生出版社, 2015: 1-20.
5. Miyashita N, Matsushima T, Oka M. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med, 2006, 45(7): 419-428.
6. Corrêa-Rde A, Lundgren FL, Pereira-Silva JL, et al. Brazilian guidelines for community-acquired pneumonia in immunocompetent adults - 2009. J Bras Pneumol, 2009, 35(6): 574-601.
7. Wiersinga WJ, Bonten MJ, Boersma WG, et al. SWAB /NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults. Neth J Med, 2012, 70(2): 90-101.
8. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis, 2007, 44(Suppl 2): 27-72.
9. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect DIS, 2000, 31(2): 347-382.
10. Tao LL, Hu BJ, He LX, et al. Etiology and antimicrobial resistance of community-acquired pneumonia in adults patients in China. Chin Med J, 2012, 125(17): 2967-2972.
11. 劉又寧, 陳民均, 趙鐵梅, 等. 中國城市成人社區獲得性肺炎 665 例病原學多中心調查. 中華結核和呼吸雜志, 2006, 29(1): 3-8.
12. 王輝, 劉亞麗, 陳民均, 等. 2009-2010 年中國六城市成人社區獲得性呼吸道感染病原菌耐藥性監測. 中華結核和呼吸雜志, 2012, 35(2): 113-119.
13. 趙春江, 張菲菲, 王占偉, 等. 2012 年中國成人社區獲得性呼吸道感染主要致病菌耐藥性的多中心研究. 中華結核和呼吸雜志, 2015, 38(1): 18-22.
14. Liu Y, Ye X, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother, 2009, 53(5): 2160-2162.
15. 尹玉東, 曹彬, 王輝, 等. 北京地區成人社區獲得性肺炎患者中肺炎支原體耐藥情況的多中心調查. 中華結核和呼吸雜志, 2013, 36(12): 954-958.
16. 尹玉東, 曹彬. 社區獲得性肺炎診治指南解讀: 從病情嚴重度分層角度. 中國循證醫學雜志, 2015, 15(7): 756-760.
17. Mills GD, Oehley MR, Arrol B. Effectiveness of β lactam antibiotics compared with antibiotics active against pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ, 2005, 330(7489): 456.
18. Eccles S, Pincus C, Higgins B, et al. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ, 2014, 349: 6722.

Chinese Journal of Evidence-Based Medicine

Drug usage and costs of pneumonia inpatients in Karamay Central Hospital in 2014

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content